Kinnunen PT, et al. - Researchers examined breast cancer (BrCa) survival in correlation with anticoagulant use via performing a nationwide cohort study. They used the national prescription database to identify all anticoagulants used from 1995 to 2015 among 73,170 women who received a diagnosis of invasive BrCa in Finland between 1995 and2013; women were selected from the Finnish Cancer Registry. Death from BrCa was reported among 15% women at a median of 5.8 years following BrCa diagnosis. Throughout the study duration, anticoagulant use was reported in 35% women. An increased risk of BrCa death was observed in relation to post-diagnostic anticoagulant use. High risk was noted particularly for low-molecular weight heparin, though vanishing of the effect was noted in long-term users. Findings revealed no clinical benefit of using anticoagulant as far as BrCa survival was concerned; however, potential survival benefits might be concealed by the link between thrombosis and cancer.